Search
Now showing items 1-9 of 9
Cost of heart failure management in Turkey: results of a Delphi Panel
(TURKISH SOC CARDIOLOGY, 2016)
Objective: To analyze health-related cost of heart failure (HF) and to evaluate health-related source utilization aiming to provide data on the economic burden of HF in actual clinical practice in Turkey. Methods: The study ...
Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study
(TURKISH SOC CARDIOLOGY, 2015)
Objective: Ischemia-modified albumin (IMA) is a sensitive biomarker of myocardial ischemia. However, data on IMA levels in acute heart failure (HF) are still lacking. In this study, we aimed to evaluate serum IMA levels ...
Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study
(TURKISH SOC CARDIOLOGY, 2016)
Objective: The present objective was to determine frequency of Arginine389Glycine (Arg389Gly) and Cytochrome p450 2D6*10 (Cyp2D6*10) polymorphism in cases of heart failure-reduced ejection fraction (HFREF), and to evaluate ...
Relation between serum sodium levels and clinical outcomes in Turkish patients hospitalized for heart failure: a multi-center retrospective observational study
(TURKISH SOC CARDIOLOGY, 2017)
Objective: The purpose of the study was to analyze the prevalence of hyponatremia and related 1-year outcomes of patients hospitalized for decompensated heart failure with reduced ejection fraction (HFrEF) in Turkish ...
Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine
(SPRINGER, 2007)
Background Levosimendan is a relatively new cardiac inotropic agent with calcium sensitizing activity. This study was conducted to investigate the effects of levosimendan (L) and dobutamine (D) on renal function in patients ...
Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure
(TURKISH SOC CARDIOLOGY, 2017)
Objective: Soluble suppression of tumorigenicity-2 (sST2), a member of the interleukin 1 receptor family, is increased in mechanical stress conditions and is produced by cardiomyocytes and cardiac fibroblasts. Elevated ...
Practical approaches for the treatment of chronic heart failure: Frequently asked questions, overlooked points and controversial issues in current clinical practice
(TURKISH SOC CARDIOLOGY, 2015)
Heart failure (HF) is a progressive disorder associated with impaired quality of life, high morbidity, mortality and frequent hospitalization and affects millions of people from all around the world. Despite further ...
Relationship between functional capacity and socioeconomic status in a cohort of Turkish heart failure patients
(TURKISH SOC CARDIOLOGY, 2016)
Objective: New York Heart Association (NYHA) classification predicts prognosis for heart failure (HF) patients. Socioeconomic status (SES) has the potential to affect treatment strategy and disease course. The present ...
Vaccination of adults with heart failure and chronic heart conditions: Expert opinion
(TURKISH SOC CARDIOLOGY, 2018)
…